Lipoic acid alleviates L‑DOPA‑induced dyskinesia in 6‑OHDA parkinsonian rats via anti‑oxidative stress

Zhang,Su‑Fang; Xie,Cheng‑Long; Lin,Jing‑Ya; Wang,Mei‑Hua; Wang,Xi‑Jin; Liu,Zhen‑Guo

doi:10.3892/mmr.2017.7974

Lipoic acid alleviates L‑DOPA‑induced dyskinesia in 6‑OHDA parkinsonian rats via anti‑oxidative stress

Authors:
- Su‑Fang Zhang
- Cheng‑Long Xie
- Jing‑Ya Lin
- Mei‑Hua Wang
- Xi‑Jin Wang
- Zhen‑Guo Liu
View Affiliations

Affiliations: Department of Neurology, Xinhua Hospital, Medical School of Shanghai Jiaotong University, Shanghai 200092, P.R. China, Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, P.R. China
Published online on: November 6, 2017 https://doi.org/10.3892/mmr.2017.7974
Pages: 1118-1124

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Levodopa (L‑DOPA) is the gold standard for symptomatic treatment of Parkinson's disease (PD); however, long‑term therapy is associated with the emergence of L‑DOPA‑induced dyskinesia (LID). Nigral dopaminergic cell loss determines the degree of drug exposure and time required for the initial onset of LID. Accumulating evidence indicates that α‑lipoic acid (ALA) decreases this nigral dopaminergic cell loss. However, until now, the precise mechanisms of ALA have only been partially understood in LID. Chronic L‑DOPA treatment was demonstrated to develop intense AIM scores to assess dyskinetic symptoms. Rats in the LID group were administrated twice daily with L‑DOPA + benserazide for 3 weeks to induce a rat model of dyskinesia. Moreover, other 6‑OHDA‑lesioned rats were treatment with ALA (31.5 mg/kg or 63 mg/kg) in combination with L‑DOPA treatment. Furthermore, the authors investigated the level of malondialdehyde (MDA) and glutathione (GSH) activity, as well as IBa‑1, caspase‑3 and poly (ADP-ribose) polymerase (PARP) in substantia nigra by the way of western blotting and immunofluorescence. ALA reduced LID in a dose‑dependent manner without compromising the anti‑PD effect of L‑DOPA. Moreover, ALA reduced the level of MDA and upregulated the GSH activity, as well as ameliorated IBa‑1 positive neurons in the substantia nigra. Finally, it was identified that ALA could reduce L‑DOPA‑induced cleaved‑caspase‑3 and PARP overexpression in the substantia nigra. Based on the present ﬁndings, ALA could be recommended as a promising disease‑modifying therapy when administered with L‑DOPA early in the course of PD. The exact mechanism for this action, although incompletely understood, appears to relate to anti‑oxidative stress and anti‑apoptosis.

View Figures

View References

1	Mosharov EV, Borgkvist A and Sulzer D: Presynaptic effects of levodopa and their possible role in dyskinesia. Mov Disord. 30:45–53. 2015. View Article : Google Scholar : PubMed/NCBI
2	Hely MA, Morris JG, Reid WG and Trafficante R: Sydney multicenter study of Parkinson's disease: Non-L-DOPA-responsive problems dominate at 15 years. Mov Disord. 20:190–199. 2005. View Article : Google Scholar : PubMed/NCBI
3	Finlay C and Duty S: Therapeutic potential of targeting glutamate receptors in Parkinson's disease. J Neural Transm (Vienna). 121:861–880. 2014. View Article : Google Scholar : PubMed/NCBI
4	Schaeffer E, Pilotto A and Berg D: Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease. CNS Drugs. 28:1155–1184. 2014. View Article : Google Scholar : PubMed/NCBI
5	Dorszewska J, Prendecki M, Lianeri M and Kozubski W: Molecular effects of L-dopa therapy in parkinson's disease. Curr Genomics. 15:11–17. 2014. View Article : Google Scholar : PubMed/NCBI
6	Spencer JP, Jenner P and Halliwell B: Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine. Relevance to Parkinson's disease. Neuroreport. 6:1480–1484. 1995. View Article : Google Scholar : PubMed/NCBI
7	Andican G, Konukoglu D, Bozluolcay M, Bayulkem K, Firtiina S and Burcak G: Plasma oxidative and inflammatory markers in patients with idiopathic Parkinson's disease. Acta Neurol Belg. 112:155–159. 2012. View Article : Google Scholar : PubMed/NCBI
8	Ferreira PM, Militão GC and Freitas RM: Lipoic acid effects on lipid peroxidation level, superoxide dismutase activity and monoamines concentration in rat hippocampus. Neurosci Lett. 464:131–134. 2009. View Article : Google Scholar : PubMed/NCBI
9	Smith AR, Shenvi SV, Widlansky M, Suh JH and Hagen TM: Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr Med Chem. 11:1135–1146. 2004. View Article : Google Scholar : PubMed/NCBI
10	De Araújo DP, Lobato Rde F, Cavalcanti JR, Sampaio LR, Araújo PV, Silva MC, Neves KR, Fonteles MM, Sousa FC and Vasconcelos SM: The contributions of antioxidant activity of lipoic acid in reducing neurogenerative progression of Parkinson's disease: A review. Int J Neurosci. 121:51–57. 2011. View Article : Google Scholar : PubMed/NCBI
11	Li DW, Li GR, Lu Y, Liu ZQ, Chang M, Yao M, Cheng W and Hu LS: α-lipoic acid protects dopaminergic neurons against MPP+-induced apoptosis by attenuating reactive oxygen species formation. Int J Mol Med. 32:108–114. 2013. View Article : Google Scholar : PubMed/NCBI
12	De Araújo DP, Lobato Rde F, Cavalcanti JR, Sampaio LR, Araújo PV, Silva MC, Neves KR, Fonteles MM, Sousa FC and Vasconcelos SM: The contributions of antioxidant activity of lipoic acid in reducing neurogenerative progression of Parkinson's disease: A review. Int J Neurosci. 121:51–57. 2011. View Article : Google Scholar : PubMed/NCBI
13	de Araújo DP, De Sousa CN, Araújo PV, Menezes CE, Rodrigues Sousa FT, Escudeiro SS, Lima NB, Patrocínio MC, Aguiar LM, Viana GS and Vasconcelos SM: Behavioral and neurochemical effects of alpha-lipoic Acid in the model of Parkinson's disease induced by unilateral stereotaxic injection of 6-ohda in rat. Evid Based Complement Alternat Med. 2013:5713782013. View Article : Google Scholar : PubMed/NCBI
14	Xie CL, Wang WW, Zhang SF, Yuan ML, Che JY, Gan J, Song L, Yuan WE and Liu ZG: Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats. Sci Rep. 4:75062014. View Article : Google Scholar : PubMed/NCBI
15	Zhang S, Xie C, Wang Q and Liu Z: Interactions of CaMKII with dopamine D2 receptors: Roles in levodopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's rats. Sci Rep. 4:68112014. View Article : Google Scholar : PubMed/NCBI
16	Deininger MH, Meyermann R and Schluesener HJ: The allograft inflammatory factor-1 family of proteins. FEBS Lett. 514:115–121. 2002. View Article : Google Scholar : PubMed/NCBI
17	Jalali-Nadoushan M and Roghani M: Alpha-lipoic acid protects against 6-hydroxydopamine-induced neurotoxicity in a rat model of hemi-parkinsonism. Brain Res. 1505:68–74. 2013. View Article : Google Scholar : PubMed/NCBI
18	Perfeito R, Cunha-Oliveira T and Rego AC: Reprint of: Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse. Free Radic Biol Med. 62:186–201. 2013. View Article : Google Scholar : PubMed/NCBI
19	Schober A: Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res. 318:215–224. 2004. View Article : Google Scholar : PubMed/NCBI
20	Norden DM, Trojanowski PJ, Villanueva E, Navarro E and Godbout JP: Sequential activation of microglia and astrocyte cytokine expression precedes increased Iba-1 or GFAP immunoreactivity following systemic immune challenge. Glia. 64:300–316. 2016. View Article : Google Scholar : PubMed/NCBI
21	D'Amelio M, Sheng M and Cecconi F: Caspase-3 in the central nervous system: Beyond apoptosis. Trends Neurosci. 35:700–709. 2012. View Article : Google Scholar : PubMed/NCBI
22	Hald A and Lotharius J: Oxidative stress and inflammation in Parkinson's disease: Is there a causal link? Exp Neurol. 193:279–290. 2005. View Article : Google Scholar : PubMed/NCBI